Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Ironwood Pharmaceuticals (Nasdaq: IRWD) raised its full-year 2026 financial guidance after reporting higher third-quarter revenue and profit alongside LINZESS sales growth. The company now expects U.S. LINZESS net sales of $1.20–$1.25 billion, revenue of $485–$510 million and adjusted EBITDA, a non-GAAP earnings measure, above $350 million.
Third-quarter revenue reached $133.04 million, versus $122.06 million a year earlier; GAAP net income rose to $59.838 million from $40.080 million. Operating cash flow increased to $130.8 million from $47.6 million. Ironwood repaid $60.0 million of revolving debt, leaving $325.0 million outstanding. Cash ended the quarter at $86.4 million, versus $215.5 million at year-end 2025. The apraglutide STARS-2 confirmatory Phase 3 trial remains ongoing; Ironwood plans a 2029 regulatory filing, subject to trial results.
Ironwood Pharmaceuticals (IRWD) will host its third-quarter 2026 investor update conference call and webcast on November 5, 2026. The call begins at 8:30 a.m. Eastern Time, with webcast access through the Investors & Media section of its website.
A telephone replay will be available from approximately 11:30 a.m. Eastern Time that day through 11:59 p.m. Eastern Time on November 19, 2026. A webcast replay will also be available on the website after the call.
Ironwood Pharmaceuticals (Nasdaq: IRWD) appointed Tammi Gaskins chief executive officer and a board member, effective January 1, 2027. Gaskins, currently chief commercial officer, will succeed Tom McCourt, who will retire from the CEO role that day and remain on the board.
Gaskins joined Ironwood in 2020 and has led commercial development efforts for apraglutide, a treatment in Phase 3 development for adults with short bowel syndrome with intestinal failure. The board credited her with helping return LINZESS to growth in 2026. McCourt joined Ironwood as its first chief commercial officer and became CEO in 2021. His tenure included the acquisition of VectivBio, which brought apraglutide into the company's late-stage pipeline. The transition follows 17 years at Ironwood for McCourt.
Ironwood Pharmaceuticals (IRWD) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10 at 10:15 a.m. ET.
A live webcast and post-event replay of the session will be available through the Investors & Media section of Ironwood’s website, www.ironwoodpharma.com.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported strong Q2 2026 results and raised full-year 2026 guidance. LINZESS U.S. net sales guidance increased to $1.15–$1.20 billion, implying >30% year-over-year growth. Total revenue guidance rose to $460–$485 million and adjusted EBITDA guidance to >$310 million.
Q2 2026 LINZESS U.S. net sales were $282.3 million (14% YoY), with collaboration revenue to Ironwood of $110.0 million (28% YoY). Total revenue was $113.0 million, GAAP net income $51.3 million and adjusted EBITDA $83.0 million. Ironwood repaid $200 million of convertible notes using cash on hand and ended the quarter with $79.1 million in cash and $385.0 million drawn on its revolving credit facility. The FDA approved LINZESS for pediatric functional constipation in May 2026, and the confirmatory Phase 3 STARS-2 trial of apraglutide in SBS-IF is now actively recruiting patients.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. U.S. participants can dial (888) 596-4144 and international callers (646) 968-2525, using conference ID and event passcode 3647053.
The live webcast and subsequent replay will be available in the Investors & Media section of Ironwood’s website. A telephone replay will run from approximately 11:30 a.m. ET on August 6, 2026 through 11:59 p.m. ET on August 20, 2026 at (800) 770-2030 with conference ID 3647053.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline will retire after a 30-year career, and that Dr. Jeffrey Silber has been appointed his successor, effective July 20, 2026. Dr. Silber will lead Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to CEO Tom McCourt, while Dr. Shetzline remains as an advisor to support a smooth transition.
Ironwood also reported that the confirmatory Phase 3 STARS-2 trial of apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF) was initiated in June and is now actively recruiting. According to the company, Dr. Silber brings extensive drug development and GI-focused experience from Vedanta Biosciences, EMD Serono/Merck KGaA, AbbVie and Merck & Co.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4 at 11:05 a.m. ET.
A live webcast and subsequent replay will be available via the Investors & Media section of Ironwood’s website.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that the FDA has approved LINZESS (linaclotide) for pediatric patients 2 years of age and older with functional constipation (FC), expanding its prior approval from 6+ years. LINZESS remains the only FDA‑approved prescription therapy for pediatric FC and received priority review for this indication.
The new approval is supported by a 12‑week Phase 3 randomized, placebo‑controlled trial in children aged 2‑5, where LINZESS 72 mcg improved spontaneous bowel movement frequency versus placebo, with a safety profile generally consistent with adult and older pediatric trials.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported Q1 2026 results: LINZESS U.S. net sales $272.5M (+97% YoY) and total revenue $106.5M. GAAP net income was $40.8M; adjusted EBITDA $76.7M. FDA granted priority review for LINZESS sNDA (PDUFA May 24, 2026). Apraglutide Phase 3 STARS-2 site initiations expected Q2 2026. Cash $220.5M; revolver balance $385.0M. 2026 guidance: U.S. LINZESS net sales $1.125–1.175B; total revenue $450–475M; adjusted EBITDA >$300M.